Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer testis antigens (CTAs), with their widesprea...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2017/6527306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568460436045824 |
|---|---|
| author | Kamel Ait-Tahar Amanda P. Anderson Martin Barnardo Graham P. Collins Chris S. R. Hatton Alison H. Banham Karen Pulford |
| author_facet | Kamel Ait-Tahar Amanda P. Anderson Martin Barnardo Graham P. Collins Chris S. R. Hatton Alison H. Banham Karen Pulford |
| author_sort | Kamel Ait-Tahar |
| collection | DOAJ |
| description | Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer testis antigens (CTAs), with their widespread expression in many tumours but highly restricted normal tissue distribution, represent attractive immunotherapeutic targets that may improve treatment options for DLBCL and other malignancies. Sperm protein 17 (Sp17), a CTA reported to be immunogenic in ovarian cancer and myeloma patients, is expressed in DLBCL. The aim of the present study was to investigate Sp17 epitope presentation via the presence of a cytotoxic T cell (CTL) and a CD4 T-helper (Th) response in DLBCL patients. A significant γ-interferon CTL response was detected in peripheral blood mononuclear cells of 13/31 DLBCL patients following short-term cell stimulation with two novel HLA-A⁎0201 peptides and one previously reported HLA-A⁎0101-restricted nine-mer Sp17 peptide. No significant responses were detected in the HLA-A⁎0201-negative DLBCL patients or four healthy subjects. A novel immunogenic 20-mer CD4 Th Sp17 peptide was detected in 8/17 DLBCL patients. This is the first report of a CTL and a CD4 Th response to Sp17 in DLBCL and supports Sp17 as a potential immunotherapeutic target for DLBCL. |
| format | Article |
| id | doaj-art-d51b6cff87684ef0aa59f3727a1873ee |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-d51b6cff87684ef0aa59f3727a1873ee2025-02-03T00:59:01ZengWileyAdvances in Hematology1687-91041687-91122017-01-01201710.1155/2017/65273066527306Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma PatientsKamel Ait-Tahar0Amanda P. Anderson1Martin Barnardo2Graham P. Collins3Chris S. R. Hatton4Alison H. Banham5Karen Pulford6Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UKNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UKTransplant Immunology & Immunogenetics, Oxford Transplant Centre, Churchill Hospital, Oxford, UKDepartment of Clinical Haematology, Churchill Hospital, Oxford, UKDepartment of Clinical Haematology, Churchill Hospital, Oxford, UKNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UKNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UKImproved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer testis antigens (CTAs), with their widespread expression in many tumours but highly restricted normal tissue distribution, represent attractive immunotherapeutic targets that may improve treatment options for DLBCL and other malignancies. Sperm protein 17 (Sp17), a CTA reported to be immunogenic in ovarian cancer and myeloma patients, is expressed in DLBCL. The aim of the present study was to investigate Sp17 epitope presentation via the presence of a cytotoxic T cell (CTL) and a CD4 T-helper (Th) response in DLBCL patients. A significant γ-interferon CTL response was detected in peripheral blood mononuclear cells of 13/31 DLBCL patients following short-term cell stimulation with two novel HLA-A⁎0201 peptides and one previously reported HLA-A⁎0101-restricted nine-mer Sp17 peptide. No significant responses were detected in the HLA-A⁎0201-negative DLBCL patients or four healthy subjects. A novel immunogenic 20-mer CD4 Th Sp17 peptide was detected in 8/17 DLBCL patients. This is the first report of a CTL and a CD4 Th response to Sp17 in DLBCL and supports Sp17 as a potential immunotherapeutic target for DLBCL.http://dx.doi.org/10.1155/2017/6527306 |
| spellingShingle | Kamel Ait-Tahar Amanda P. Anderson Martin Barnardo Graham P. Collins Chris S. R. Hatton Alison H. Banham Karen Pulford Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients Advances in Hematology |
| title | Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients |
| title_full | Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients |
| title_fullStr | Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients |
| title_full_unstemmed | Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients |
| title_short | Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients |
| title_sort | sp17 protein expression and major histocompatibility class i and ii epitope presentation in diffuse large b cell lymphoma patients |
| url | http://dx.doi.org/10.1155/2017/6527306 |
| work_keys_str_mv | AT kamelaittahar sp17proteinexpressionandmajorhistocompatibilityclassiandiiepitopepresentationindiffuselargebcelllymphomapatients AT amandapanderson sp17proteinexpressionandmajorhistocompatibilityclassiandiiepitopepresentationindiffuselargebcelllymphomapatients AT martinbarnardo sp17proteinexpressionandmajorhistocompatibilityclassiandiiepitopepresentationindiffuselargebcelllymphomapatients AT grahampcollins sp17proteinexpressionandmajorhistocompatibilityclassiandiiepitopepresentationindiffuselargebcelllymphomapatients AT chrissrhatton sp17proteinexpressionandmajorhistocompatibilityclassiandiiepitopepresentationindiffuselargebcelllymphomapatients AT alisonhbanham sp17proteinexpressionandmajorhistocompatibilityclassiandiiepitopepresentationindiffuselargebcelllymphomapatients AT karenpulford sp17proteinexpressionandmajorhistocompatibilityclassiandiiepitopepresentationindiffuselargebcelllymphomapatients |